Clinical Trial

A Study to Evaluate the Efficacy and Safety of IBI302inSubjects With nAMD

Name: A Study to Evaluate the Efficacy and Safety of IBI302inSubjects With nAMD — clinical trial record (NCT07275840)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

This study is designed for Open-label, multi-center, single-arm Phase II trail to evaluate the efficacy and safety of intravitreal injection of IBI302 in nAMD patients.

Protocol Amendment History 1 amendment

This ClinicalTrials.gov record has been amended once since 2025-12-08.

Status change: Not Yet Recruiting → Recruiting 2026-01-07

Trial Details

NCT Number	NCT07275840
Lead Sponsor	Innovent Biologics Technology Limited (Shanghai R&D Center)
Conditions	Neovascular Age-related Macular Degeneration
Enrollment	800 participants
Start Date	2025-12-05
Primary Completion	2026-08-30 (estimated)
Study Completion	2026-08-30 (estimated)
Updated on ClinicalTrials.gov	2026-01-08